Company logo

ITCI - Intra-Cellular Therapies, Inc.

NASDAQ -> Healthcare -> Drug Manufacturers—Specialty & Generic
New York, United States
Type: Equity

ITCI price evolution
ITCI
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $695.06 $141.57 $149.52
Short term investments $329.6 $335.8 $350.17
Net receivables $145.61 $145.71 $131.16 $114.02
Inventory $23.54 $52.64 $50.77 $50.27
Total current assets $1271.73 $1264.25 $690.53 $667.8
Long term investments
Property, plant & equipment $16.02 $15.95 $14 $14.58
Goodwill & intangible assets
Total noncurrent assets $56.25 $56.51 $60.5
Total investments $329.6 $335.8 $350.17
Total assets $1324.44 $1320.5 $747.04 $728.29
Current liabilities
Accounts payable $10.34 $17.55 $11.53 $11.45
Deferred revenue
Short long term debt $4.17 $3.64 $3.61
Total current liabilities $166.11 $161.78 $134.8 $123.55
Long term debt $14.12 $12.74 $13.33
Total noncurrent liabilities $14.12 $12.74 $13.33
Total debt $18.29 $16.38 $16.94
Total liabilities $179.62 $175.89 $147.54 $136.87
Shareholders' equity
Retained earnings -$1674.95 -$1648.63 -$1632.41 -$1617.16
Other shareholder equity $1.63 -$0.67 -$0.43 $0.1
Total shareholder equity $1144.61 $599.5 $591.42
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $149.52 $150.37 $93.76 $61.45
Short term investments $350.17 $443.29 $319.97 $597.4
Net receivables $114.02 $75.19 $20.16 $10.76
Inventory $50.27 $23.92 $7.95 $7.06
Total current assets $667.8 $737.96 $467.28 $690.9
Long term investments
Property, plant & equipment $14.58 $16.74 $22.56 $26.32
Goodwill & intangible assets
Total noncurrent assets $60.5 $16.82 $22.64 $26.41
Total investments $350.17 $443.29 $319.97 $597.4
Total assets $728.29 $754.78 $489.92 $717.31
Current liabilities
Accounts payable $11.45 $10.39 $8.69 $5.5
Deferred revenue
Short long term debt $3.61 $4.57 $6.73 $5.54
Total current liabilities $123.55 $83.24 $53.36 $36.85
Long term debt $13.33 $15.47 $18.67 $23.6
Total noncurrent liabilities $13.33 $15.47 $18.67 $23.6
Total debt $16.94 $20.04 $25.41 $29.14
Total liabilities $136.87 $98.71 $72.03 $60.45
Shareholders' equity
Retained earnings -$1617.16 -$1477.49 -$1221.23 -$937.1
Other shareholder equity $0.1 -$4.19 -$0.36 $0.48
Total shareholder equity $591.42 $656.07 $417.89 $656.86
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $161.39 $144.87 $132.1
Cost of revenue $11.35 $9.9 $10.7
Gross Profit $150.03 $134.97 $121.4
Operating activities
Research & development $56.18 $42.83 $50.77
Selling, general & administrative $121.57 $113.08 $104.72
Total operating expenses $177.76 $155.92 $155.49
Operating income -$27.72 -$20.95 -$34.1
Income from continuing operations
EBIT -$16.16 -$14.89 -$28.13
Income tax expense $0.06 $0.36 $0.45
Interest expense
Net income
Net income -$16.22 -$15.25 -$28.58
Income (for common shares) -$16.22 -$15.25 -$28.58
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $464.37 $250.31 $83.8 $22.81
Cost of revenue $33.74 $20.44 $8.03 $1.9
Gross Profit $430.63 $229.87 $75.77 $20.92
Operating activities
Research & development $180.14 $134.72 $88.85 $65.78
Selling, general & administrative $409.86 $358.78 $272.61 $186.36
Total operating expenses $590.01 $493.5 $361.46 $252.15
Operating income -$159.38 -$263.63 -$285.69 -$231.23
Income from continuing operations
EBIT -$139.04 -$256.25 -$284.12 -$226.99
Income tax expense $0.64 $0.01 $0.01 $0.01
Interest expense
Net income
Net income -$139.67 -$256.26 -$284.13 -$227.01
Income (for common shares) -$139.67 -$256.26 -$284.13 -$227.01
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$16.22 -$15.25 -$28.58
Operating activities
Depreciation $0.13 $0.13 $0.14
Business acquisitions & disposals
Stock-based compensation $16.39 $13.87 $14.88
Total cash flows from operations $0.54 -$34.12 -$2.06
Investing activities
Capital expenditures -$0.05 -$0
Investments $7.82 $16.18 $47.42
Total cash flows from investing -$185.26 $7.77 $16.18 $47.42
Financing activities
Dividends paid
Sale and purchase of stock $545.18 $9.99 $3
Net borrowings
Total cash flows from financing $561.9 $545.18 $9.99 $3
Effect of exchange rate
Change in cash and equivalents $316.55 $553.49 -$7.95 $48.37
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$139.67 -$256.26 -$284.13 -$227.01
Operating activities
Depreciation $0.53 $0.66 $0.53 $0.53
Business acquisitions & disposals
Stock-based compensation $52.92 $43.1 $34.48 $24.33
Total cash flows from operations -$124.2 -$270.19 -$259.54 -$230.07
Investing activities
Capital expenditures -$0.27 -$0.78 -$0.33 -$0.27
Investments $105.81 -$127.59 $280.67 -$480.03
Total cash flows from investing $105.54 -$128.37 $280.34 -$480.3
Financing activities
Dividends paid
Sale and purchase of stock $17.81 $455.16 $11.52 $664.18
Net borrowings
Total cash flows from financing $17.81 $455.16 $11.52 $664.18
Effect of exchange rate
Change in cash and equivalents -$0.85 $56.6 $32.32 -$46.19
Fundamentals
Market cap $8.85B
Enterprise value N/A
Shares outstanding 106.00M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 0.23
Net debt/EBITDA N/A
Current ratio 7.66
Quick ratio 7.51